We crystallise small-molecule drugs in low Earth orbit — where crystals grow more uniform and more stable than Earth can reliably achieve — and deliver the material back to our pharmaceutical partners.
Most drugs are crystals, and the crystal form decides how well a drug works. For a stubborn minority of molecules, the best-performing form is unstable or inconsistent on Earth.
Why orbit changes this →Gravity drives convection and sedimentation — the hidden sources of crystal defects. In orbit, crystals grow by pure diffusion: larger, more uniform, with fewer defects.
Already demonstrated in orbit →A standard API supply relationship: hand over a molecule, receive better material. The entire space operation is ours, end to end.
How the platform works →A superior crystal form creates value at two moments in a drug's life.
When the form that works best is metastable, or won't stay consistent batch to batch, the route to market closes. Orbital crystallisation can reopen it — better dissolution and bioavailability, reduced variability, a stronger manufacturing position.
A differentiated, patentable crystal form a generic cannot copy gives prescribers a clinical reason to stay with the brand — and the owner a way to hold market share past the cliff.
Zero Gravity Works is participating in the ESA Business Incubation Centre Milan
Orbital pharmaceutical manufacturing has just turned commercial. Zero Gravity Works is building the European play on top of it — from Milan, supported by ESA BIC and an advisory network across eight universities.
Write to info [at] zerogravityworks [dot] com